You are here

Article info

Article menu

Download PDFPDF

Commentary
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors

Authors

  • Laurent Mathiot Drug Development Department, Gustave Roussy, Villejuif, Île-de-France, France PubMed articlesGoogle scholar articles
  • David Combarel Laboratoire de pharmacologie, Département de Biologie et Pathologie Médicales, Gustave Roussy, Villejuif, Île-de-France, FranceFaculté de pharmacie, Université Paris-Saclay, Orsay, France PubMed articlesGoogle scholar articles
  • Justin Cagnat Drug Development Department, Gustave Roussy, Villejuif, Île-de-France, France PubMed articlesGoogle scholar articles
  • Julia Delahousse Laboratoire de pharmacologie, Département de Biologie et Pathologie Médicales, Gustave Roussy, Villejuif, Île-de-France, France PubMed articlesGoogle scholar articles
  • Kaissa Ouali Drug Development Department, Gustave Roussy, Villejuif, Île-de-France, France PubMed articlesGoogle scholar articles
  • Aurelien Marabelle Drug Development Department, Gustave Roussy, Villejuif, Île-de-France, FranceFaculté de médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, FranceU1015, INSERM, Villejuif, FranceCentre d’Investigations Cliniques Biothérapies pour une immunisation in situ (BIOTHERIS) CIC1428, INSERM, Villejuif, France PubMed articlesGoogle scholar articles
  • Yohann Loriot Drug Development Department, Gustave Roussy, Villejuif, Île-de-France, FranceFaculté de médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, FranceU981, INSERM, Villejuif, France PubMed articlesGoogle scholar articles
  • Santiago Ponce Drug Development Department, Gustave Roussy, Villejuif, Île-de-France, France PubMed articlesGoogle scholar articles
  • Stephane Champiat Drug Development Department, Gustave Roussy, Villejuif, Île-de-France, FranceU1015, INSERM, Villejuif, FranceCentre d’Investigations Cliniques Biothérapies pour une immunisation in situ (BIOTHERIS) CIC1428, INSERM, Villejuif, France PubMed articlesGoogle scholar articles
  • Sophie Broutin Laboratoire de pharmacologie, Département de Biologie et Pathologie Médicales, Gustave Roussy, Villejuif, Île-de-France, FranceFaculté de pharmacie, Université Paris-Saclay, Orsay, France PubMed articlesGoogle scholar articles
  • Francois-Xavier Danlos Drug Development Department, Gustave Roussy, Villejuif, Île-de-France, FranceFaculté de médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, FranceU1015, INSERM, Villejuif, FranceCentre d’Investigations Cliniques Biothérapies pour une immunisation in situ (BIOTHERIS) CIC1428, INSERM, Villejuif, France PubMed articlesGoogle scholar articles

Citation

Mathiot L, Combarel D, Cagnat J, et al
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors
Journal for ImmunoTherapy of Cancer 2024;12:e008847. doi: 10.1136/jitc-2024-008847
Online issue publication 
May 03, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.